News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
102,564 Results
Type
Article (6297)
Company Profile (20)
Press Release (96247)
Multimedia
Podcasts (1)
Webinars (1)
Section
Business (30901)
Career Advice (199)
Deals (4780)
Drug Delivery (5)
Drug Development (8952)
Employer Resources (11)
FDA (2902)
Job Trends (2935)
News (49836)
Policy (5462)
Tag
2024 BioCapital Digital (1)
2024 BioMidwest Digital (2)
2024 Bio NC Digital (3)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Standard (1)
2025 Lone Star Bio Digital (1)
Academia (665)
Academic (1)
Allergies (14)
Alliances (9968)
ALS (6)
Alzheimer's disease (187)
Antibody-drug conjugate (ADC) (16)
Approvals (2943)
Artificial intelligence (33)
Automation (9)
Bankruptcy (26)
Best Places to Work (2273)
BIOSECURE Act (1)
Biosimilars (5)
Biotechnology (14)
Bladder cancer (10)
Brain cancer (4)
Breast cancer (50)
Cancer (356)
Cardiovascular disease (21)
Career advice (183)
Career pathing (1)
CAR-T (21)
Cell therapy (49)
Cervical cancer (9)
Clinical research (6964)
Collaboration (150)
Compensation (2)
Complete response letters (3)
COVID-19 (549)
CRISPR (5)
C-suite (21)
Cystic fibrosis (7)
Data (293)
Depression (1)
Diabetes (22)
Diagnostics (3159)
Digital health (1)
Diversity, equity & inclusion (1)
Drug discovery (20)
Drug pricing (2)
Drug shortages (1)
Duchenne muscular dystrophy (8)
Earnings (8914)
Employer branding (3)
Employer resources (9)
Events (10259)
Executive appointments (104)
FDA (3051)
Featured Employer (4)
Frontotemporal dementia (1)
Funding (80)
Gene editing (8)
Generative AI (3)
Gene therapy (33)
GLP-1 (103)
Government (900)
Grass and pollen (3)
Guidances (5)
Healthcare (2282)
Immunology and inflammation (5)
Indications (4)
Infectious disease (578)
Inflammatory bowel disease (7)
Influenza (12)
Intellectual property (11)
Interviews (24)
IPO (1421)
Job creations (775)
Job search strategy (174)
Kidney cancer (1)
Labor market (2)
Layoffs (31)
Leadership (1)
Legal (1113)
Liver cancer (8)
Lung cancer (62)
Lymphoma (26)
Machine learning (1)
Management (3)
Manufacturing (52)
MASH (3)
Medical device (1366)
Medtech (1366)
Mergers & acquisitions (3433)
Metabolic disorders (44)
Multiple sclerosis (3)
NASH (1)
Neurodegenerative disease (11)
Neuropsychiatric disorders (1)
Neuroscience (222)
NextGen: Class of 2025 (792)
Non-profit (579)
Northern California (246)
Now hiring (11)
Obesity (19)
Opinion (14)
Ovarian cancer (4)
Pain (7)
Pancreatic cancer (8)
Parkinson's disease (14)
Partnered (4)
Patents (18)
Patient recruitment (6)
Peanut (9)
People (9361)
Pharmaceutical (6)
Phase I (2039)
Phase II (2679)
Phase III (2712)
Pipeline (139)
Policy (4)
Postmarket research (393)
Preclinical (1186)
Press Release (18)
Prostate cancer (21)
Psychedelics (2)
Radiopharmaceuticals (29)
Rare diseases (31)
Real estate (1969)
Recruiting (4)
Regulatory (3757)
Reports (7)
Research institute (631)
Resumes & cover letters (19)
RSV (4)
Series A (11)
Series B (7)
Sickle cell disease (5)
Southern California (257)
Spinal muscular atrophy (34)
Sponsored (6)
Startups (602)
State (1)
Stomach cancer (2)
Supply chain (10)
Tariffs (1)
The Weekly (1)
United States (2682)
Vaccines (51)
Venture capitalists (1)
Weight loss (12)
Women's health (3)
Date
Today (23)
Last 7 days (71)
Last 30 days (271)
Last 365 days (3975)
2025 (1095)
2024 (4405)
2023 (5253)
2022 (8593)
2021 (8967)
2020 (8740)
2019 (6088)
2018 (4735)
2017 (5147)
2016 (5256)
2015 (5806)
2014 (4673)
2013 (4156)
2012 (4414)
2011 (4476)
2010 (3994)
Location
Africa (124)
Alabama (10)
Alaska (1)
Arizona (34)
Arkansas (2)
Asia (6356)
Australia (1064)
California (627)
Canada (249)
China (28)
Colorado (36)
Connecticut (30)
Delaware (26)
Europe (13926)
Florida (84)
Georgia (10)
Idaho (6)
Illinois (40)
India (3)
Indiana (37)
Iowa (2)
Japan (19)
Kansas (21)
Kentucky (4)
Louisiana (1)
Maine (24)
Maryland (102)
Massachusetts (393)
Michigan (59)
Minnesota (32)
Missouri (35)
Montana (9)
Nebraska (3)
Nevada (3)
New Hampshire (7)
New Jersey (272)
New Mexico (8)
New York (209)
North Carolina (145)
North Dakota (1)
Northern California (246)
Ohio (38)
Oklahoma (3)
Oregon (3)
Pennsylvania (112)
Rhode Island (10)
South America (177)
South Carolina (4)
Southern California (257)
Tennessee (17)
Texas (162)
Utah (41)
Virginia (12)
Washington D.C. (4)
Washington State (82)
Wisconsin (9)
102,564 Results for "galderma laboratories".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
February 14, 2025
·
13 min read
Press Releases
Galderma’s Nemluvio® (Nemolizumab) Granted Marketing Authorization in the United Kingdom and Switzerland for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
February 18, 2025
·
7 min read
Press Releases
AMWC 2025: Galderma Pushes the Innovation Frontier With Updates From Its Unparalleled Portfolio Designed to Meet the Needs of the Aesthetic Community
March 20, 2025
·
16 min read
Press Releases
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union
December 13, 2024
·
14 min read
Press Releases
AAD 2025: Galderma to Present Extensive Updates From Across Its Dermatology Portfolio, Demonstrating Its Category Leadership and Strong Momentum
March 3, 2025
·
10 min read
Press Releases
IMCAS 2025: New Galderma Phase IIIb Data Reinforce Rapid Onset and Long-lasting Aesthetic Improvement with RelabotulinumtoxinA (Relfydess™)
January 31, 2025
·
6 min read
Press Releases
Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis
November 28, 2024
·
10 min read
Press Releases
ASDS 2024: New Phase III READY-4 Data Demonstrate Long-Term Safety and Efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™)
October 21, 2024
·
9 min read
Press Releases
Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis
December 16, 2024
·
14 min read
Immunology and inflammation
Galderma’s IL-31 Injection Wins FDA Approval for Skin Disorder Prurigo Nodularis
The Swiss company’s monoclonal antibody Nemluvio is also undergoing regulatory review for atopic dermatitis, which is a potentially larger market for the first-in-class IL-31 blocker.
August 13, 2024
·
2 min read
·
Tristan Manalac
1 of 10,257
Next
